Preeti Joseph, MD
Neurology · Dubuque, IANPI 1730229121
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,389 of the $12,758 with a category attached, or 73.6%. 49 manufacturers reported payments, led by Novartis at 25.8% of the total. Reporting peaked in 2020 at $3,889 and has fallen 59.9% since, to $1,561 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Livanova USA, Inc.$777
- Teva Pharmaceuticals USA, Inc.$674
- Merz Pharmaceuticals, LLC$522
- Acadia Pharmaceuticals Inc$447
- Pfizer$428
- plus $7K from 43 others
What the payments were for
- Speaking & faculty fees$200%
- Travel & lodging$3783%
- Food & beverage$9,38974%
- Education$1111%
- Gifts$2,85922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAYZENT$2,670
- VNS Therapy$621
- GOCOVRI$170
- ACTIVA$168
How this compares
$12,758 in reported general payments places this provider in the 90th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 29 | $60,024 |
| Aimovig AutoinjectorErenumab-Aooe | 36 | $33,260 |
| BriviactBrivaracetam | 15 | $29,355 |
| UbrelvyUbrogepant | 25 | $26,977 |
| Emgality PenGalcanezumab-Gnlm | 17 | $15,363 |
| Lamotrigine ErLamotrigine | 25 | $15,214 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 248 | $7,987 |
| Memantine Hcl | 304 | $7,874 |
| Gabapentin | 277 | $6,602 |
| Levetiracetam | 167 | $6,128 |
| Lacosamide | 19 | $4,732 |
| Levetiracetam ErLevetiracetam | 39 | $3,900 |
| Pyridostigmine Bromide | 22 | $2,896 |
| Duloxetine Hcl | 151 | $2,783 |
| Donepezil Hcl | 224 | $2,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $447 | $60,02429 claims |
| UCB, Inc.Briviact | $423 | $29,35515 claims |
| AbbVieUbrelvy | $405 | $26,97725 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $105 | $2,89622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 neurology providers in Iowa.
Other neurology in Dubuque
- Laurie GarmsDubuque$2K
- Paula AstonDubuque$747
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
- Douglas NathansonIowa City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.